Cooper Companies (The) (COO) Research

Forward Estimates

EPS Estimates

Current Qtr

$1.12

$1.10$1.14

vs $1.10+1.8%

14 analysts

Next Qtr

$1.19

$1.16$1.22

vs $1.15+3.9%

14 analysts

Current Yr

$4.63

$4.57$4.67

vs $4.12+12.3%

16 analysts

Next Yr

$5.00

$4.85$5.10

vs $4.63+8.1%

16 analysts

Revenue Estimates

Current Qtr

$1.10B

$1.09B$1.11B

vs $1.06B+3.6%

14 analysts

Next Qtr

$1.11B

$1.10B$1.11B

vs $1.07B+3.8%

14 analysts

Current Yr

$4.31B

$4.30B$4.33B

vs $4.09B+5.3%

16 analysts

Next Yr

$4.52B

$4.46B$4.60B

vs $4.31B+4.9%

16 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for COO on EDGAR.

COO filing events and research context
Filed	Item	Context
Dec 5, 2025	business	The Cooper Companies is a global medical device firm operating through two primary segments: CooperVision and CooperSurgical. CooperVision manufactures a comprehensive range of contact lenses, including spherical, toric, and multifocal designs, with a strategic focus on silicone hydrogel materials and myopia management. Its flagship MiSight 1 day lens is a key differentiator, holding FDA, NMPA, and MHLW approvals to slow myopia progression in children. CooperSurgical provides a diversified portfolio of over 600 products and services spanning fertility, women’s health, and medical devices. Its offerings include IVF laboratory equipment, genomic services, cryostorage, and the hormone-free Paragard IUD. The company faces intense competition from major players like Johnson & Johnson, Alcon, and Bausch + Lomb, and must navigate a complex regulatory landscape, including FDA oversight and evolving EU MDR/IVDR requirements. Financial performance is sensitive to healthcare consolidation trends, which are shifting procurement toward group practices and integrated delivery networks. Key risks include reliance on sole-source suppliers for certain components, potential volatility in reimbursement coverage, and the impact of healthcare reform legislation on pricing. The company maintains a global footprint with over 15,000 employees and continues to pursue growth through both internal innovation and strategic acquisitions in the fertility and vision sectors.
Dec 5, 2025	mda	The Cooper Companies reported a 5% increase in consolidated net sales for fiscal 2025, driven by growth in both CooperVision and CooperSurgical segments. CooperVision, which accounts for the majority of revenue, saw gains in its silicone hydrogel contact lens portfolio, particularly through the MyDay and Biofinity franchises. The company is aggressively pursuing market penetration in myopia management, highlighted by the global expansion of its MiSight 1 day lens, which has secured regulatory approvals in China and Japan. CooperSurgical’s growth was supported by strong performance in fertility services and genomic testing, alongside contributions from the Paragard contraceptive line and the acquisition of obp Surgical. Despite top-line growth, consolidated gross margin contracted to 66% from 67%, primarily due to inventory write-offs and workforce optimization costs. Operating income faced pressure from these same restructuring expenses and increased R&D investment, which rose 11% to support product innovation. The company maintains a solid liquidity position, supported by $796.1 million in operating cash flow and access to a $2.3 billion revolving credit facility. Management remains focused on capital allocation, evidenced by the recent increase in the share repurchase authorization to $2.0 billion, while navigating risks including inflation, supply chain volatility, and shifting global trade barriers.
Dec 5, 2025	risk_factors	The Cooper Companies faces a range of macroeconomic and operational risks that could materially impact its financial performance. Global business, political, and economic instability—including inflation, pandemic-related disruptions, and supply chain volatility—pose ongoing threats to sales and cash flow. The company is particularly sensitive to foreign exchange rate fluctuations, given its extensive international operations and exposure to currencies such as the British pound, Euro, and Japanese yen. Additionally, escalating global trade barriers and tariffs could disrupt its manufacturing and distribution networks. Operationally, CooperVision’s success depends on its ability to compete in the global contact lens market, specifically through its silicone hydrogel product franchises like clariti, MyDay, and Biofinity. The company faces pressure to maintain market share against competitors by successfully navigating the industry shift toward single-use modalities and expanding its presence in myopia management, notably with its FDA-approved MiSight 1 day lens. CooperSurgical faces risks related to technological obsolescence and the need for continuous innovation in its fertility and women’s health portfolios. Furthermore, the company’s reliance on debt to fund acquisitions and operations exposes it to interest rate risk, while its decentralized manufacturing structure requires rigorous internal controls to ensure accurate financial reporting and inventory management.

Filed

Item

Context

Dec 5, 2025

business

The Cooper Companies is a global medical device firm operating through two primary segments: CooperVision and CooperSurgical. CooperVision manufactures a comprehensive range of contact lenses, including spherical, toric, and multifocal designs, with a strategic focus on silicone hydrogel materials and myopia management. Its flagship MiSight 1 day lens is a key differentiator, holding FDA, NMPA, and MHLW approvals to slow myopia progression in children. CooperSurgical provides a diversified portfolio of over 600 products and services spanning fertility, women’s health, and medical devices. Its offerings include IVF laboratory equipment, genomic services, cryostorage, and the hormone-free Paragard IUD. The company faces intense competition from major players like Johnson & Johnson, Alcon, and Bausch + Lomb, and must navigate a complex regulatory landscape, including FDA oversight and evolving EU MDR/IVDR requirements. Financial performance is sensitive to healthcare consolidation trends, which are shifting procurement toward group practices and integrated delivery networks. Key risks include reliance on sole-source suppliers for certain components, potential volatility in reimbursement coverage, and the impact of healthcare reform legislation on pricing. The company maintains a global footprint with over 15,000 employees and continues to pursue growth through both internal innovation and strategic acquisitions in the fertility and vision sectors.

Dec 5, 2025

mda

The Cooper Companies reported a 5% increase in consolidated net sales for fiscal 2025, driven by growth in both CooperVision and CooperSurgical segments. CooperVision, which accounts for the majority of revenue, saw gains in its silicone hydrogel contact lens portfolio, particularly through the MyDay and Biofinity franchises. The company is aggressively pursuing market penetration in myopia management, highlighted by the global expansion of its MiSight 1 day lens, which has secured regulatory approvals in China and Japan. CooperSurgical’s growth was supported by strong performance in fertility services and genomic testing, alongside contributions from the Paragard contraceptive line and the acquisition of obp Surgical. Despite top-line growth, consolidated gross margin contracted to 66% from 67%, primarily due to inventory write-offs and workforce optimization costs. Operating income faced pressure from these same restructuring expenses and increased R&D investment, which rose 11% to support product innovation. The company maintains a solid liquidity position, supported by $796.1 million in operating cash flow and access to a $2.3 billion revolving credit facility. Management remains focused on capital allocation, evidenced by the recent increase in the share repurchase authorization to $2.0 billion, while navigating risks including inflation, supply chain volatility, and shifting global trade barriers.

Dec 5, 2025

risk_factors

The Cooper Companies faces a range of macroeconomic and operational risks that could materially impact its financial performance. Global business, political, and economic instability—including inflation, pandemic-related disruptions, and supply chain volatility—pose ongoing threats to sales and cash flow. The company is particularly sensitive to foreign exchange rate fluctuations, given its extensive international operations and exposure to currencies such as the British pound, Euro, and Japanese yen. Additionally, escalating global trade barriers and tariffs could disrupt its manufacturing and distribution networks. Operationally, CooperVision’s success depends on its ability to compete in the global contact lens market, specifically through its silicone hydrogel product franchises like *clariti*, *MyDay*, and *Biofinity*. The company faces pressure to maintain market share against competitors by successfully navigating the industry shift toward single-use modalities and expanding its presence in myopia management, notably with its FDA-approved *MiSight 1 day* lens. CooperSurgical faces risks related to technological obsolescence and the need for continuous innovation in its fertility and women’s health portfolios. Furthermore, the company’s reliance on debt to fund acquisitions and operations exposes it to interest rate risk, while its decentralized manufacturing structure requires rigorous internal controls to ensure accurate financial reporting and inventory management.

Forward Estimates

COO filing events and research context

Keep researching COO

Related tickers

Related explainers

Forward Estimates